Dosing Anti-TfR1 Oligonucleotide Complexes for Muscle DMPK Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for myotonic dystrophy type 1 (DM1) are ineffective, and there is a need for a therapeutic approach to reduce DMPK expression or activity, which is associated with the disease's pathogenesis.
Innovation Solution
Administering muscle-targeting complexes comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to oligonucleotides to target and reduce DMPK expression in muscle cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for myotonic dystrophy type 1, then treatment is provided, but the therapy is ineffective
Solution Approach 1:
The patent changes the molecular parameters of the therapy by using anti-TfR1 antibody conjugates with specific oligonucleotide sequences (including modified nucleosides like LNA, MOE, or 2'-fluoro) that target DMPK RNA with high affinity. This parameter change enables effective reduction of DMPK expression, resolving the issue of therapeutic ineffectiveness.
Solution Approach 2:
The patent introduces an intermediary mechanism by using the anti-TfR1 antibody as a delivery vehicle that mediates the transport of oligonucleotide payloads to muscle cells. The antibody binds to TfR1 receptors on muscle cell surfaces, facilitating targeted delivery and enabling effective therapeutic action where previous therapies failed.
2Reliability
If oligonucleotide therapies are administered, then DMPK expression is reduced, but the complexity of the therapeutic composition increases
Solution Approach 1:
The patent merges the oligonucleotide therapeutic payload with the anti-TfR1 antibody delivery vehicle into a single conjugate complex. This combining approach achieves effective DMPK expression reduction while managing composition complexity through a standardized conjugation methodology that links the oligonucleotide to the antibody via a stable connection.
Solution Approach 2:
The patent creates a composite therapeutic material consisting of the anti-TfR1 antibody conjugated to oligonucleotide sequences. This composite structure integrates the targeting and delivery functions of the antibody with the molecular mechanism of the oligonucleotide, achieving effective DMPK reduction through a unified therapeutic composition.
3Reliability
If muscle-targeting complexes are administered, then therapeutic effect is achieved, but the dosing requirements and administration complexity increase
Solution Approach 1:
The patent incorporates feedback mechanisms through the anti-TfR1 antibody's specific binding to TfR1 receptors on muscle cells, which provides targeted delivery feedback. This feedback system ensures that the therapeutic oligonucleotide is delivered specifically to the intended target cells, achieving reliable therapeutic effect while simplifying the overall administration process compared to non-targeted approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces DMPK RNA and protein levels in muscle cells, leading to potential therapeutic benefits for myotonic dystrophy.
Implementation Method 1
complexes comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to one or more oligonucleotides
Data Source
AI summary
Aspects of the disclosure relate to methods of reducing expression or activity of DMPK (e.g., reducing the level of a mutant or wild-type DMPK RNA, or the activity of a DMPK gene product) and/or methods of treating myotonic dystrophy (e.g., DM1) in a subject. In some embodiments, the methods comprise administering to the subject a composition comprising complexes (e.g., muscle targeting complexes) comprising an oligonucleotide (e.g., a DMPK—targeting oligonucleotide) covalently linked to an antibody (e.g., anti-TfR1 antibody).